Thymoma is a rare mediastinal tumor that originates from thymic epithelial cells. The current treatment of thymoma depends on the benign and malignant degree of the tumor. Thymic carcinoma is very rare, it is invasive, the prognosis is poor, and the patient has a short survival time. At present, there is no standard treatment mode. Most scholars prefer comprehensive treatment. Anlotinib is a new type of small-molecule multi-target tyrosine kinase inhibitor independently developed by China. It has anti-tumor angiogenesis and inhibits tumor growth, and has good safety and tolerance. Anlotinib can be used for the treatment of advanced thymic cancer, or it can achieve the purpose of treatment. We report a case of patients with advanced thymic cancer who responded to anlotinib hydrochloride after failing third-line treatment. The patient was diagnosed with advanced thymic cancer (stage IVb) in our hospital on March 10, 2016. She was given cisplatin + paclitaxel for 4 cycles, followed by sequential chest and neck radiotherapy. The second line was given 6 cycles of cyclophosphamide + pirorubium Bistar + Nedaplatin chemotherapy; three lines of 4 cycles of gemcitabine + nedaplatin chemotherapy; four lines of anilotinib monotherapy, as of the latest review, the patient's progression-free survival reached 10 months. Rotini is light and safe and controllable. This is the first report of anlotinib hydrochloride in the treatment of advanced thymic cancer. More clinical studies are still needed to confirm the efficacy and safety of anlotinib in the treatment of thymic cancer.

Amare Jain and Saader Metawan. Case Report of Anlotinib in Advanced Thymic Cancer. International Journal of Health and Pharmaceutical Medicine (2020), Vol. 1, Issue 4: 64-79. https://doi.org/10.38007/IJHPM.2020.010406.

[1] Fu H, Gu Z, Fang W, et al. Long-Term Survival After Surgical Treatment of Thymic Carcinoma: A Retrospective Analysis from the Chinese Alliance for Research of Thymoma Database. Annals of surgical oncology, 2016, 23(2):619-625. https://doi.org/10.1245/s10434-015-4825-4

[2] Nobuyasu Kurihara, Hajime Saito, Hiroshi Nanjo. Thymic carcinoma with myasthenia gravis: Two case reports. International Journal of Surgery Case Reports, 2016, 27(C):110-112. https://doi.org/10.1016/j.ijscr.2016.08.010

[3] R.-Q. Wang, Y.-H. Zhang. Advances in clinical research of antitumor targeting drug anlotinib. Chinese Journal of New Drugs, 2018, 27(23):2770-2774.

[4] Yen-Han Tseng, Yi-Hsuan Lin, Yen-Chiang Tseng. Adjuvant Therapy for Thymic Carcinoma – A Decade of Experience in a Taiwan National Teaching Hospital. Plos One, 2016, 11(1):e0146609. https://doi.org/10.1371/journal.pone.0146609

[5] Ko R, Shukuya T, Okuma Y, et al. Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study. Oncologist,2018,23(10):1210-1217. https://doi.org/10.1634/theoncologist.2017-0586

[6] Hirai F, Yamanaka T, Taguchi K, et al. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol,2015,26(2):363-368. https://doi.org/10.1093/annonc/mdu541

[7] Yang Y, Fan X W, Wang H B, et al. Stage IVb thymic carcinoma: patients with lymph node metastases have better prognoses than those with hematogenous metastases. BMC Cancer,2017,17(1):217. https://doi.org/10.1186/s12885-017-3228-2

[8] Kayata H, Isaka M, Ohde Y, et al. Complete Resection of Masaoka Stage IVb Thymic Carcinoma After Chemoradiotherapy. Ann Thorac Surg,2017,103(1):e5-e7. https://doi.org/10.1016/j.athoracsur.2016.05.048

[9] Katsuya Y, Fujita Y, Horinouchi H, et al. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer,2015,88(2):154-159. https://doi.org/10.1016/j.lungcan.2015.03.003

[10] Marx A, Chan J K, Coindre J M, et al. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. J Thorac Oncol,2015,10(10):1383-1395. https://doi.org/10.1097/JTO.0000000000000654

[11] Giaccone G, Kim C, Thompson J, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol,2018,19(3):347-355. https://doi.org/10.1016/S1470-2045(18)30062-7

[12] Cho J, Kim H S, Ku B M, et al. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. J Clin Oncol,2019,37(24):2162-2170. https://doi.org/10.1200/JCO.2017.77.3184

[13] Enkner F, Pichlhofer B, Zaharie A T, et al. Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets. Pathol Oncol Res,2017,23(3):551-564. https://doi.org/10.1007/s12253-016-0144-8

[14] Karube Y, Kobayashi S, Maeda S, et al. Tumor-related gene expression levels in thymic carcinoma and Type B3 thymoma. J Cardiothorac Surg,2016,11(1):85. https://doi.org/10.1186/s13019-016-0468-1

[15] Ming Zhou, Xiaoyuan Chen, Hong Zhang. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Communications, 2019, 39(1):36. https://doi.org/10.1186/s40880-019-0383-7

[16] Taurin S, Yang C H, Reyes M, et al. Abstract 3244: Treatment of endometrial cancer cells with a new small tyrosine kinase inhibitor targeting mutated fibroblast growth factor receptor-2. 2017, 77(13 Supplement):3244-3244. https://doi.org/10.1158/1538-7445.AM2017-3244

[17] Yang C H, Gaffney D K, Werner T L, et al. Abstract 1756: Genomic reclassification of endometrial carcinoma predicts drug response and facilitates refinement of current management based on PDX-guided efficacy outcomes. 2017, 77(13 Supplement):1756-1756. https://doi.org/10.1158/1538-7445.AM2017-1756

[18] Yajuan Lv, Jiandong Zhang, Fengjun Liu. Targeted therapy with anlotinib for patient with recurrent glioblastoma: A case report and literature review. Medicine, 2019, 98(22):e15749. https://doi.org/10.1097/MD.0000000000015749

[19] Teresa Bellissimo, Emanuele Russo, Federica Ganci. Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors. Cancer Biology & Therapy, 2015, 17(1):79-82. https://doi.org/10.1080/15384047.2015.1108493

[20] Brett W Carter, Marcelo F Benveniste, Rachna Madan. IASLC/ITMIG staging system and lymph node map for thymic epithelial neoplasms. Radiographics A Review Publication of the Radiological Society of North America Inc, 2017, 37(3):758-776. https://doi.org/10.1148/rg.2017160096

[21] Gokce Simsek, Istemihan Akin, Cem Saka. Thymoma with an incidental benign laryngeal mass mimicking laryngeal carcinoma: Case report. Ear Nose & Throat Journal, 2016, 95(2):68-80.

[22] Li Li, Yeye Chen, Shanqing Li. [Primary Neuroendocrine Carcinoma of Thymus Caused Cushing Syndrome: Surgical Treatment and Prognosis Analysis]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2015, 18(3):451-456.

[23] Thomas A, Rajan A, Berman A, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma:  an open-label phase 2 trial. Lancet Oncol,2015,16(2):177-186. https://doi.org/10.1016/S1470-2045(14)71181-7

[24] Bolzacchini E, Chini C, Pinotti G. Response of Malignant Thymoma to Sorafenib. J Thorac Oncol,2016,11(10):e125-e126. https://doi.org/10.1016/j.jtho.2016.07.011

[25] Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1. Gene,2018,654:77-86. https://doi.org/10.1016/j.gene.2018.02.026

[26] Han B, Li K, Wang Q, et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol,2018,4(11):1569-1575. https://doi.org/10.1001/jamaoncol.2018.3039

[27] Sun Y, Du F, Gao M, et al. Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer. Thyroid,2018,28(11):1455-1461. https://doi.org/10.1089/thy.2018.0022

[28] Mohammed I. Alghamdi, Neutrosophic set with Adaptive Neuro-Fuzzy Inference System for Liver Tumor Segmentation and Classification Model, International Journal of Neutrosophic Science, 2022, Vol. 18, No. 2, pp: 174-185 .https://doi.org/10.54216/IJNS.180202 

[29] P. Kavitha , R. Subha Shini , R. Priya, An Implementation Of Statistical Feature Algorithms For The Detection Of Brain Tumor, Journal of Cognitive Human-Computer Interaction, 2021, Vol. 1, No. 2, pp: 57 - 62 .https://doi.org/10.54216/JCHCI.010202

[30] Ahmed N. Al Masri , Hamam Mokayed, An Efficient Machine Learning based Cervical Cancer Detection and Classification, Journal of Cybersecurity and Information Management, 2020, Vol. 2, No. 2, pp: 58-67 .https://doi.org/10.54216/JCIM.020203

[31] Cao, J., van Veen, E. M., Peek, N., Renehan, A. G., & Ananiadou, S. (2021, June). EPICURE: Ensemble Pretrained Models for Extracting Cancer Mutations from Literature. In 2021 IEEE 34th International Symposium on Computer-Based Medical Systems (CBMS) (pp. 461-467). IEEE. https://doi.org/10.1109/CBMS52027.2021.00054